Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies

References

• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9(2):182–15. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT: Pharmacometrics & Syst Pharmacol. 2017;6:576–88.
   PubMedGoogle Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58. doi:10.1038/clpt.2008.170.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68. doi:10.1002/jps.20178.
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12(1):33–43. doi:10.1208/s12248-009-9157-5.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–88. doi:10.1016/S1359-6446(05)03638-X.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861–71. doi:10.1158/1535-7163.MCT-09-0195.
   PubMed Web of Science ®Google Scholar
• Betts A, van der Graaf PH. Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology. Clin Pharmacol Ther. 2020;108(3):528–41. doi:10.1002/cpt.1961.
   PubMed Web of Science ®Google Scholar
• Fu R, Carroll L, Yahioglu G, Aboagye EO, Miller PW. Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications. ChemMedChem. 2018;13(23):2466–78. doi:10.1002/cmdc.201800624.
   PubMed Web of Science ®Google Scholar
• Sham JG, Kievit FM, Grierson JR, Chiarelli PA, Miyaoka RS, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3–Targeting F(ab′)2 for 89 Zr PET of hepatocellular carcinoma. J Nucl Med. 2014;55(12):2032–37. doi:10.2967/jnumed.114.145102.
   PubMed Web of Science ®Google Scholar
• Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, Bouwman WH, van der Graaf WT, Oyen WJ, Boerman OC. Optimization of IGF-1R SPECT/CT imaging using 111 in-labeled F(ab′) 2 and fab fragments of the monoclonal antibody R1507. Mol Pharm. 2012;9(8):2314–21. doi:10.1021/mp300232n.
   PubMedGoogle Scholar
• Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, et al. Optimizing radiolabeled engineered Anti-p185 HER2 antibody fragments for in vivo imaging. Cancer Res. 2005;65(13):5907–16. doi:10.1158/0008-5472.CAN-04-4472.
   PubMed Web of Science ®Google Scholar
• Olafsen T, Sirk SJ, Olma S, Shen CK, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour biol:J Int Soc Oncodevelopmental Biol Med. 2012;33(3):669–77. doi:10.1007/s13277-012-0365-8.
   PubMed Web of Science ®Google Scholar
• Chakravarty R, Goel S, Valdovinos HF, Hernandez R, Hong H, Nickles RJ, Cai W. Matching the decay Half-Life with the biological Half-Life: immunoPET imaging with 44 Sc-Labeled cetuximab fab fragment. Bioconjug Chem. 2014;25(12):2197–204. doi:10.1021/bc500415x.
   PubMed Web of Science ®Google Scholar
• Holloway CM, Scollard DA, Caldwell CB, Ehrlich L, Kahn HJ, Reilly RM. Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab fab fragments. Nucl Med Biol. 2013;40(5):630–37. doi:10.1016/j.nucmedbio.2013.03.005.
   PubMed Web of Science ®Google Scholar
• Xavier C, Vaneycken I, D’Huyvetter M, Heemskerk J, Keyaerts M, Vincke C, Devoogdt N, Muyldermans S, Lahoutte T, Caveliers V, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68 Ga-NOTA-Anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54(5):776–84. doi:10.2967/jnumed.112.111021.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, Tolmachev V, Orlova A, Sörensen J, Carlsson J, et al. Biodistribution and radiation dosimetry of the Anti-HER2 affibody molecule 68 Ga-ABY-025 in breast cancer patients. J Nucl Med. 2016;57(6):867–71. doi:10.2967/jnumed.115.169342.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Marik J, Elowson MJ, Reyes NA, Ulufatu S, Bumbaca D, Yip V, Mundo EE, Majidy N, Van Hoy M, et al. Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies. J Med Chem. 2013;56(23):9418–26. doi:10.1021/jm401365h.
   PubMed Web of Science ®Google Scholar
• Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, Gotthardt M, Boerman OC. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51(7):1049–58. doi:10.2967/jnumed.110.075101.
   PubMed Web of Science ®Google Scholar
• Levitt DG. The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003;3(1):3. doi:10.1186/1472-6904-3-3.
   PubMedGoogle Scholar
• Wiig H, Tenstad O, Iversen PO, Kalluri R, Bjerkvig R. Interstitial fluid: the overlooked component of the tumor microenvironment? Fibrogenesis Tissue Repair. 2010;3(1):12. doi:10.1186/1755-1536-3-12.
   PubMedGoogle Scholar
• Benias PC, Wells RG, Sackey-Aboagye B, Klavan H, Reidy J, Buonocore D, Miranda M, Kornacki S, Wayne M, Carr-Locke DL, et al. Structure and distribution of an unrecognized interstitium in human tissues. Sci Rep. 2018;8(1):4947. doi:10.1038/s41598-018-23062-6.
   PubMedGoogle Scholar
• Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J. 2012;14(3):612–18. doi:10.1208/s12248-012-9374-1.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA. Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PloS one. 2011;6(3):e17874. doi:10.1371/journal.pone.0017874.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, Theil, FP, Fielder, PJ, Khawli, LA . Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharm. 2010;7(5):1848–57. doi:10.1021/mp100183k.
   PubMedGoogle Scholar
• Mandikian D, Figueroa I, Oldendorp A, Rafidi H, Ulufatu S, Schweiger MG, Couch JA, Dybdal N, Joseph SB, Prabhu S, et al. Tissue physiology of cynomolgus monkeys: cross-Species comparison and implications for translational pharmacology. AAPS J. 2018;20(6):107. doi:10.1208/s12248-018-0264-z.
   PubMed Web of Science ®Google Scholar
• Eigenmann MJ, Fronton L, Grimm HP, Otteneder MB, Krippendorff BF. Quantification of IgG monoclonal antibody clearance in tissues. mAbs. 2017;9(6):1007–15. doi:10.1080/19420862.2017.1337619.
   PubMed Web of Science ®Google Scholar
• Eigenmann MJ, Karlsen TV, Krippendorff BF, Tenstad O, Fronton L, Otteneder MB, Wiig H. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo - and physiologically-based pharmacokinetic modelling approaches. J Physiol. 2017;595(24):7311–30. doi:10.1113/JP274819.
   PubMed Web of Science ®Google Scholar
• Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice. Cancer Res. 1986;46:3969–78.
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, Larson SM, Keenan AM. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci. 1987;507(1 Biological Ap):199–210. doi:10.1111/j.1749-6632.1987.tb45802.x.
   PubMedGoogle Scholar
• Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54:1517–28.
   PubMed Web of Science ®Google Scholar
• Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55:4611–22.
   PubMed Web of Science ®Google Scholar
• Li Z, Li Y, Chang HP, Chang HY, Guo L, Shah DK. Effect of size on solid tumor disposition of protein therapeutics. Drug Metab Dispos. 2019;47(10):1136–45. doi:10.1124/dmd.119.087809.
   PubMed Web of Science ®Google Scholar
• Li Z, Li Y, Chang HP, Yu X, Shah DK. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice. J Pharmacokinet Pharmacodyn. 2021;48(5):743–62. doi:10.1007/s10928-021-09772-x.
   PubMed Web of Science ®Google Scholar
• Li Z, Yu X, Li Y, Verma A, Chang HP, Shah DK. A Two-Pore physiologically based pharmacokinetic model to predict subcutaneously administered Different-Size antibody/antibody fragments. AAPS J. 2021;23(3):62. doi:10.1208/s12248-021-00588-8.
   PubMed Web of Science ®Google Scholar
• Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, Prabhu S, et al. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. mAbs. 2014;6(3):689–96. doi:10.4161/mabs.28254.
   PubMed Web of Science ®Google Scholar
• Chen N, Wang W, Fauty S, Fang Y, Hamuro L, Hussain A, Prueksaritanont T. The effect of the neonatal Fc receptor on human IgG biodistribution in mice. mAbs. 2014;6(2):502–08. doi:10.4161/mabs.27765.
   PubMed Web of Science ®Google Scholar
• Li Z, Krippendorff BF, Shah DK. Influence of molecular size on the clearance of antibody fragments. Pharm Res. 2017;34(10):2131–41. doi:10.1007/s11095-017-2219-y.
   PubMed Web of Science ®Google Scholar
• Li Z, Krippendorff BF, Sharma S, Walz AC, Lave T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. mAbs. 2016;8(1):113–19. doi:10.1080/19420862.2015.1111497.
   PubMed Web of Science ®Google Scholar
• Li Z, Shah DK. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics. J Pharmacokinet Pharmacodyn. 2019;46(3):305–18. doi:10.1007/s10928-019-09639-2.
   PubMed Web of Science ®Google Scholar
• Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang N-Y, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013;110(32):E2987–96. doi:10.1073/pnas.1302725110.
   PubMed Web of Science ®Google Scholar
• Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622–31.
   PubMed Web of Science ®Google Scholar
• Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res. 2007;67(2):718–26. doi:10.1158/0008-5472.CAN-06-0454.
   PubMed Web of Science ®Google Scholar
• Rafidi H, Estevez A, Ferl GZ, Mandikian D, Stainton S, Sermeño L, Williams SP, Kamath AV, Koerber JT, Boswell CA, et al. Imaging reveals importance of shape and flexibility for glomerular filtration of biologics. Mol Cancer Ther. 2021;20(10):2008–15. doi:10.1158/1535-7163.MCT-21-0116.
   PubMed Web of Science ®Google Scholar
• Shivva V, Boswell CA, Rafidi H, Kelley RF, Kamath AV, Crowell SR. Antibody format and serum disposition govern ocular pharmacokinetics of intravenously administered protein therapeutics. Front Pharmacol. 2021;12:601569. doi:10.3389/fphar.2021.601569.
   PubMed Web of Science ®Google Scholar
• Klingler S, Fay R, Holland JP. Light-Induced radiosynthesis of 89 Zr-DFO-Azepin-Onartuzumab for imaging the hepatocyte growth factor receptor. J Nucl Med. 2020;61(7):1072–78. doi:10.2967/jnumed.119.237180.
   PubMed Web of Science ®Google Scholar
• Fay R, Gut M, Holland JP. Photoradiosynthesis of 68 Ga-Labeled HBED-CC-Azepin-MetMAb for Immuno-PET of c-MET receptors. Bioconjug Chem. 2019;30(6):1814–20. doi:10.1021/acs.bioconjchem.9b00342.
   PubMed Web of Science ®Google Scholar
• Gill H, Seipert R, Carroll VM, Gouasmat A, Yin J, Ogasawara A, de Jong I, Phan MM, Wang X, Yang J. The production, quality control, and characterization of ZED8, a CD8-Specific 89Zr-Labeled Immuno-PET clinical imaging agent. AAPS J. 2020;22(2):22. doi:10.1208/s12248-019-0392-0.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, Manova-Todorova K, Deen WM, Scheinberg DA, McDevitt MR, et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A. 2010;107(27):12369–74. doi:10.1073/pnas.0913667107.
   PubMed Web of Science ®Google Scholar
• Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs. 2013;5(6):896–903. doi:10.4161/mabs.26436.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63. doi:10.1021/bc100261d.
   PubMed Web of Science ®Google Scholar
• Holton OD 3rd, Black CD, Parker RJ, Covell DG, Barbet J, Sieber SM, Talley MJ, Weinstein JN. Biodistribution of monoclonal IgG1, F(ab’)2, and Fab’ in mice after intravenous injection. comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. J Immunol. 1987;139(9):3041–49.
   PubMed Web of Science ®Google Scholar
• Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs. 2013;5(2):297–305. doi:10.4161/mabs.23684.
   PubMed Web of Science ®Google Scholar
• Chang HP, Kim SJ, Shah DK. Whole-Body pharmacokinetics of antibody in mice determined using Enzyme-Linked immunosorbent assay and derivation of tissue interstitial concentrations. J Pharm Sci. 2021;110(1):446–57. doi:10.1016/j.xphs.2020.05.025.
   PubMed Web of Science ®Google Scholar
• Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, and Welch MJ. Identification of metabolites of 111In-diethylene- triaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995;55:5714s–20s.
   PubMed Web of Science ®Google Scholar
• Tsai SW, Li L, Williams LE, Anderson AL, Raubitschek AA, Shively JE. Metabolism and renal clearance of 111 In-Labeled DOTA-Conjugated antibody fragments. Bioconjug Chem. 2001;12(2):264–70. doi:10.1021/bc0000987.
   PubMed Web of Science ®Google Scholar
• Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Mattes MJ. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35(5):899–908.
   PubMed Web of Science ®Google Scholar
• Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, Old LJ, Toomre DK, Scott AM. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia (New York, NY). 2007;9(12):1099–110. doi:10.1593/neo.07721.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P. Differential effects of predosing on tumor and tissue uptake of an 111 In-Labeled Anti-TENB2 Antibody–Drug conjugate. J Nucl Med. 2012;53(9):1454–61. doi:10.2967/jnumed.112.103168.
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, Ulufatu S, Bagri A, Theil F-P, Fielder PJ, et al. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol. 2012;166(1):368–77. doi:10.1111/j.1476-5381.2011.01777.x.
   PubMed Web of Science ®Google Scholar
• Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012;11(3):752–62. doi:10.1158/1535-7163.MCT-11-0742-T.
   PubMed Web of Science ®Google Scholar
• Wilbur DS, Hadley SW, Hylarides MD, Abrams PG, Beaumier PA, Morgan AC, Reno, AC, Fritzberg, AR . Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer. J Nucl Med. 1989;30:216–26.
   PubMed Web of Science ®Google Scholar
• Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C, et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry. 1986;25(26):8343–47. doi:10.1021/bi00374a001.
   PubMed Web of Science ®Google Scholar
• Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WL, Rowland AM, Kotts CE, Carver ME, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/technol (Nature Publishing Company). 1992;10(2):163–67. doi:10.1038/nbt0292-163.
   PubMedGoogle Scholar
• Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods. 2002;263(1–2):133–47. doi:10.1016/S0022-1759(02)00036-4.
   PubMed Web of Science ®Google Scholar
• Wong AW, Baginski TK, Reilly DE. Enhancement of DNA uptake in FUT8-deleted CHO cells for transient production of afucosylated antibodies. Biotechnol Bioeng. 2010;106(5):751–63. doi:10.1002/bit.22749.
   PubMed Web of Science ®Google Scholar
• Zarzar J, Shatz W, Peer N, Taing R, McGarry B, Liu Y, Greene DG, Zarraga IE. Impact of polymer geometry on the interactions of protein-PEG conjugates. Biophys Chem. 2018;236:22–30. doi:10.1016/j.bpc.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Chizzonite R, Truitt T, Podlaski FJ, Wolitzky AG, Quinn PM, Nunes P, Stern AS, Gately MK. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J Immunol. 1991;147:1548–56.
   PubMed Web of Science ®Google Scholar
• Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, et al. Relative target affinities of T Cell-Dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. Mol Cancer Ther. 2018;17(4):776–85. doi:10.1158/1535-7163.MCT-17-0657.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Kalluri R. Physiology of the renal interstitium. Clin J Am Soc Nephrol. 2015;10(10):1831–40. doi:10.2215/CJN.00640114.
   PubMed Web of Science ®Google Scholar
• Reuter S, Schnockel U, Schroter R, Schober O, Pavenstadt H, Schafers M, Gabriels G, Schlatter E. Non-invasive imaging of acute renal allograft rejection in rats using small animal F-FDG-PET. PloS one. 2009;4(4):e5296. doi:10.1371/journal.pone.0005296.
   PubMed Web of Science ®Google Scholar
• Yao X, Hrabetová S, Nicholson C, Manley GT. Aquaporin-4-deficient mice have increased extracellular space without tortuosity change. J Neurosci: off J Society Neurosci. 2008;28(21):5460–64. doi:10.1523/JNEUROSCI.0257-08.2008.
   PubMed Web of Science ®Google Scholar